Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992 Sep;51(9):1039-43.
doi: 10.1136/ard.51.9.1039.

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study

K P Machold  1 , K Neumann, J S Smolen
Affiliations
Clinical Trial

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study

K P Machold et al. Ann Rheum Dis. 1992 Sep.

Abstract

Interferon gamma (IFN gamma) has been advocated in open studies as a beneficial remission inducing drug for the treatment of rheumatoid arthritis (RA). The work reported here was designed to assess the therapeutic potential of IFN gamma in the treatment of RA in a double blind placebo controlled study. It was found that patients treated with IFN gamma improved significantly with respect to morning stiffness, grip strength, swelling of an index joint, and erythrocyte sedimentation rate. Furthermore significantly more responders (according to predetermined response criteria) were found in the group treated with IFN gamma. Only minor adverse effects and no significant toxicity with respect to clinical or laboratory parameters were observed.

PubMed Disclaimer

References

    1. Fed Proc. 1987 Jan;46(1):113-7 - PubMed
    1. Arthritis Rheum. 1989 Aug;32(8):964-73 - PubMed
    1. Dtsch Med Wochenschr. 1985 Nov 15;110(46):1766-9 - PubMed
    1. Lancet. 1973 Feb 10;1(7798):275-80 - PubMed
    1. Lancet. 1981 Oct 17;2(8251):839-42 - PubMed

Publication types